Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis-Reference-Cited by-同舟云学术

Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis

Published:2019-03 Issue:3 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Turner Nicholas¹²^ORCID,Strand Andrew¹³,Grewal Dilraj S.⁴,Cox Gary¹,Arif Sana¹,Baker Arthur W.¹²,Maziarz Eileen K.¹,Saullo Jennifer H.¹,Wolfe Cameron R.¹

Affiliation:

1. Duke University School of Medicine, Division of Infectious Diseases, Durham, North Carolina, USA

2. Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA

3. Tufts Medical Center, Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, USA

4. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, USA

Abstract

Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown.

Funder

Antibacterial Resistance Leadership Group

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02337-18

Reference17 articles.

1. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study

2. A Single-center Experience With Ganciclovir-resistant Cytomegalovirus in Lung Transplant Recipients: Treatment and Outcome

3. The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection